Table 2 Univariate analyses of significant biomarkers for PFS and OS in 48 bmCRPC-patients on Enzalutamide-therapy without PSA-response
Progression Free Survival | Overall Survival | ||||
|---|---|---|---|---|---|
Variable | HR (95% CI) | P | Variable | HR (95% CI) | P |
Visceral metastases Yes No | 1 (reference) 0.71 (0.37–1.36) | 0.30 | Visceral metastases Yes No | 1 (reference) 0.95 (0.46–1.94) | 0.88 |
Enzalutamide after chemotherapy Yes No | 1 (reference) 0.48 (0.25–0.92) | 0.03 | Enzalutamide after chemotherapy Yes No | 1 (reference) 0.31 (0.15–0.65) | < 0.01 |
Gleason-Score ≥ 8 No Yes | 1 (reference) 1.22 (0.62–2.37) | 0.57 | Gleason-Score ≥ 8 No Yes | 1 (reference) 1.27 (0.62–2.58) | 0.52 |
LDH normalization Yes No | 1 (reference) 0.94 (0.44–2.03) | 0.88 | LDH normalization Yes No | 1 (reference) 1.60 (0.71–3.65) | 0.26 |
ALP rising at 12 weeks Yes No | 1 (reference) 0.51 (0.27–0.98) | 0.04 | ALP rising at 12 weeks Yes No | 1 (reference) 0.47 (0.25–0.91) | 0.02 |
ALP rising at 12 weeks, without LDH normalization Yes No | 1 (reference) 0.48 (0.25–0.94) | 0.03 | ALP rising at 12 weeks, without LDH normalization Yes No | 1 (reference) 0.36 (0.19–0.71) | < 0.01 |
ECOG > 0 Yes No | 1 (reference) 0.67 (0.36–1.23) | 0.19 | ECOG > 0 Yes No | 1 (reference) 0.71 (0.38–1.32) | 0.28 |
Age > 70 years Yes No | 1 (reference) 0.66 (0.36–1.18) | 0.16 | Age > 70 years Yes No | 1 (reference) 0.73 (0.4–1.37) | 0.33 |
Abbreviations: PFS: progression-free survival; OS: overall survival; HR: hazard ratio; 95% CI: 95% confidence interval; ALP: alkaline phosphatase; LDH: lactate dehydrogenase; bmCRPC: bone metastatic castration-resistant prostate cancer; PSA: prostate specific antigen, ECOG: eastern cooperative oncology group performance status | |||||